Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology
+$0.15 today
- Market cap
- $336.08M
- Beta
- -0.09
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$11.26
Volume 0.18M
Average 0.09M
Returns on capital
Lyell Immunopharma, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-110.6%
avg -49.3%
ROIC
-68.0%
avg -38.1%
ROA
-80.7%
avg -38.5%
Analysis
ROIC is currently the strongest return metric at -68.0% versus its period average of -38.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Lynn Seely | Principal Executive Officer, President, CEO & Director | USD 1.13M | 67 | 63.35K | 0.27% |
Stephen J. Hill | Chief Operating Officer | USD 830.56K | 55 | 16.73K | 0.07% |
Gary Lee | Chief Scientific Officer | USD 786.81K | 49 | — | — |
Richard D. Klausner | Founder & Executive Chairman | USD 85K | 74 | — | — |
Crystal L. Mackall | Founder & Scientific Advisor | — | 65 | — | — |
Ann Tomlin | Chief Human Resources Officer | — | — | — | — |
Smital Shah | Principal Financial Officer, CFO & Chief Business Officer | — | 50 | 0 | <0.01% |
Mark A. Meltz | General Counsel & Corporate Secretary | — | 52 | 50.00K | 0.21% |
Nellie Dillery | Director of Accounting | — | — | — | — |
Stanley R. Riddell | Founder & Scientific Advisor | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$75.00M
Sells
29
$612,747.03
Net Transaction Value
+$74.39M
Net buying
Most Active
Lee Gary K.
6 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 10, 26Nov 10, 2026 | Lee Gary K. Direct | Sell | $2.1K$2,054.97 |
| Nov 10, 26Nov 10, 2026 | Hill Stephen J. Direct | Sell | $1.4K$1,401.84 |
| Nov 10, 26Nov 10, 2026 | Seely Lynn Direct | Sell | $8.7K$8,681.85 |
| Nov 10, 26Nov 10, 2026 | Bulis Veronica Sanchez Direct | Sell | $6.6K$6,626.88 |
| Nov 4, 26Nov 4, 2026 | ARCH Venture Partners IX, LLC Indirect | Buy | $25M$24,999,991.74 |
| Nov 4, 26Nov 4, 2026 | ARCH Venture Fund XIII, L.P. Indirect | Buy | $25M$24,999,991.74 |
| Oct 12, 26Oct 12, 2026 | Aguirre Jarrad Mattieu Direct | Sell | $3.6K$3,641.86 |
| Sep 10, 26Sep 10, 2026 | Shook David Direct | Sell | $6.4K$6,350.00 |
| Aug 21, 26Aug 21, 2026 | Seely Lynn Direct | Sell | $149K$149,013.06 |
| Aug 21, 26Aug 21, 2026 | Hill Stephen J. Direct | Sell | $15.4K$15,369.06 |
1–10 of 33
Summary
Insiders reported 4 buys worth $75.00M and 29 sells worth $612,747.03 over the last 12 months. That adds up to net buying of $74.39M. Lee Gary K. was the most active insider with 6 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -92.5% | +511.4% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -92.5% over three years. Forward estimates point to Revenue at +511.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Lyell Immunopharma, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about LYEL's management, answered from reported figures.
Who manages LYEL?
Lyell Immunopharma, Inc. (LYEL) lists 10 active executives. The top listed executive is Crystal L. Mackall, Founder & Scientific Advisor.
Are LYEL insiders buying or selling?
Recent insider activity shows net buying of $102.84M.
Continue the stock analysis
Jump to another research area for this company.